profit from every $100 of sales.
$0$100
Canopy Growth
$0.56-2.20% today
-49.0% in 1 year
1-year low $0.561-year high $1.92
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Canopy Growth sold, what it kept, and what it did with the cash.
Sales went from CA$476 million in 2022 to CA$269 million in 2025, with -CA$598 million of profit last year.
SalesProfit
Canopy Growth vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Canopy Growth | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Canopy Growth's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 476 | 333 | 297 | 269 | |
| -187 | -64 | 81 | 80 | |
| -638 | -396 | -128 | -66 | |
| -53 | -2,880 | -313 | -479 | |
| -310 | -3,278 | -657 | -598 | |
| -7.70 | -70.70 | -8.79 | -5.56 | |
| -39.4% | -19.1% | 27.2% | 29.6% | |
| -134.2% | -118.8% | -43.1% | -24.7% | |
| -65.2% | -983.7% | -221.2% | -222.4% |
Balance sheet
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 5,605 | 2,440 | 1,300 | 918 |
| Cash | 776 | 668 | 170 | 114 |
| Total debt | 1,640 | 1,414 | 668 | 348 |
| Total liabilities | 1,985 | 1,680 | 800 | 430 |
| 3,584 | 758 | 500 | 487 | |
| 39 | 46 | 75 | 108 | |
| -2.5% | -107.7% | -24.7% | -49.4% | |
| -8.7% | -432.2% | -131.4% | -122.8% |
Cash flow
| In millions of CAD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -546 | -558 | -282 | -166 | |
| 48 | 10 | 4 | 11 | |
| -594 | -568 | -286 | -177 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 47 | 25 | 14 | -4 |
Valuation
- –
- –
- –
- 0.7×
- 1.3×
- –
- –
- -49.2%
- -166.1%
- 0.0%
Profitability
- 29.6%
- -24.7%
- -222.4%
- -88.2%
- -6.9%
- -63.6%
- -52.9%
- -29.5%
- -7.0%
- –
Growth
- −17.3%
- –
- +38.1%
- –
- −26.8%
Financial health
- –
- 0.36
- 24.6%
- -1.7×
- 5.34
- 4.26
- 0.25
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 946
Bottom 11%of 871
Bottom 6%of 867
Bottom 1%of 986
What analysts expect
- Average price target
- $14.47
- Range
- $8.00 – $27.85
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| Feb 6, 2026 | -0.10 | -0.03 | −233.3% |
| Nov 7, 2025 | -0.01 | -0.11 | +90.9% |
| Aug 8, 2025 | -0.14 | -0.15 | +6.7% |
| May 30, 2025 | -0.94 | -0.10 | −840.0% |
| Feb 7, 2025 | -0.76 | -0.38 | −100.0% |
| Nov 8, 2024 | -0.95 | -0.38 | −150.0% |
| Aug 9, 2024 | -0.37 | -0.31 | −19.4% |
| May 30, 2024 | -0.28 | -0.33 | +15.2% |
News
Trump's Marijuana Order Is Stuck at the DEA. Here's What That Means for Canopy Growth.Yahoo Finance · Oct 18, 2026Should You Buy Canopy Growth Stock on the Rebound?Yahoo Finance · Sep 5, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
74Pass
Philip Fisher
32No pass
Peter Lynch
25No pass
Joel Greenblatt
0No pass
Charlie Munger
30No pass
Terry Smith
21No pass
Questions about Canopy Growth
Is Canopy Growth a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Canopy Growth AI analysis
What does Canopy Growth do?
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It is in Drug Manufacturers - Specialty & Generic.
Does Canopy Growth pay a dividend?
No. Canopy Growth does not pay a dividend at the moment.
Is Canopy Growth stock halal?
No. Canopy Growth does not pass our halal screen: its debt is 97% of its market value, at or above the 33% limit. How we check
How has Canopy Growth stock done over the past year?
Down 49.0% over the past twelve months, to $0.56. It traded between $0.56 and $1.92 and is 70.8% below its high.
Who are Canopy Growth's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Canopy Growth's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.